Nine-gene molecular signature is not associated with prostate cancer death in a watchful waiting cohort

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 1, 2008, Pages 249-251

  Mucci, Lorelei A ^a,b,c   Pawitan, Yudi ^e   Demichelis, Francesca ^a,c,f   Fall, Katja ^e   Stark, Jennifer R ^a,b   Adami, Hans Olov ^b,e   Andersson, Swen Olof ^g   Andrén, Ove ^g   Eisenstein, Anna S ^a   Holmberg, Lars ^h   Huang, Wei ^a,c   Kantoff, Philip W ^c,d   Perner, Sven ^a,c,i,j   Stampfer, Meir J ^a,b,c   Johansson, Jan Erik ^g   Rubin, Mark A ^a,c,d,j  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e KAROLINSKA INSTITUTE   (Sweden)

^f ITC IRST   (Italy)

^g ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^h UPPSALA UNIVERSITY   (Sweden)

ⁱ UNIVERSITY OF ULM   (Germany)

^j Department of Obstetrics Gynecology   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GENETICS; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RISK FACTOR;

AGED; COHORT STUDIES; GENE EXPRESSION PROFILING; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 38849165855     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-0722     Document Type: Article

References (16)

1. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293:2095-101.
2. Johansson JE, Andren O, Andersson SO, et al. Natural history of early, localized prostate cancer. JAMA 2004;291:2713-9.
3. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766-71.
4. Stephenson AJ, Scardino PT, Eastham JA, et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006;98:715-7.
5. Kattan MW, Shariat SF, Andrews B, et al. The addition of interleukin-6 soluble receptor and transforming growth factor β1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol 2003;21:3573-9.
6. Varambally S, Yu J, Laxman B, et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005;8:393-406.
7. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7.
8. Andren O, Fall K, Franzen L, Andersson SO, Johansson JE, Rubin MA. How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden. J Urol 2006;175:1337-40.
9. Rubin MA, Bismar TA, Andren O, et al. Decreased α-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death. Cancer Epidemiol Biomarkers Prev 2005;14:1424-32.
10. Kim R, Demichelis F, Tang J, et al. Internet-based Profiler system as integrative framework to support translational research. BMC Bioinformatics 2005;6:304.
11. D'Amico AV, Cote K, Loffredo M, Renshaw AA, Chen MH. Pretreatment predictors of time to cancer specific death after prostate specific antigen failure. J Urol 2003;169:1320-4.
12. D'Amico AV, Cote K, Loffredo M, Renshaw AA, Schultz D. Determinants of prostate cancer specific survival following radiation therapy during the prostate specific antigen era. J Urol 2003;170:S42-6; discussion S46-7.
13. Albertsen PC, Hanley JA, Barrows GH, et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 2005;97:1248-53.
14. Cuzick J, Fisher G, Kattan M, et al. Long-term outcome among men with conservatively treated localized prostate cancer. Br J Cancer 2006;95:1186-94.
15. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004;351:125-35.
16. D'Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005;294:440-7.